Cost-effectiveness Analysis on Five Regimens of Antibacterial Drug Therapy in the Treatment of Community Acquired Pneumonia

OBJECTIVE: To evaluate the cost-effectiveness of five regimens of antibacterial drug therapy in the treatment of community acquired pneumonia. METHODS: A retrospective study was conducted, in which a total of 128 cases with pneumonia were enrolled and randomly assigned to receive each of the following 5 therapies,cefoperazone sodium/ sulbactam sodium(Group A),levofloxacin(Group B),amoxicillin/ clavulanate potassium(Group C),azithromycin plus ceftazidime(Group D),and cefoxitin(Group E),the therapeutic effects were monitored and the cost-effectiveness analyses were conducted on the five groups. RESULTS: The costs of the five regimens were 2 137.0 yuan, 1 393.0 yuan, 1 152.5yuan, 2 044.2 yuan and 1 827.0 yuan, respectively;The effective rates were 85.2%, 86.6%, 80.6%, 89.6% and 78.5%, respectively;The cost-effectiveness ratios were 25.08 , 16.09, 14.30, 22.82 and 23.27, respectively; As compared with group C, the incremental cost-effectiveness ratios of the other four groups were 214.02,40.08, 99.08 and —321.19, respectively. CONCLUSION: The therapy of amoxicillin/ potassium clavulanate is superior to the other regimes in the treatment of community acquired pneumonia.